Influence
May 7, 2024

Effect of modernized collaborative care for depression on depressive symptoms and cardiovascular disease risk biomarkers: eIMPACT randomized controlled trial

Dr. Chris Callahan

Published in the journal Brain, Behavior and Immunity. Here is a link to the article.

Regenstrief Institute authors: Christopher M. Callahan, M.D., Sumedha Gupta, PhD, (affiliated scientist), Sujuan Gao, PhD, (affiliated scientist)

In a randomized controlled trial of 216 primary care patients with depression and elevated cardiovascular risk, a modernized collaborative care intervention significantly improved depressive symptoms compared to usual care. However, no changes were observed in cardiovascular disease (CVD) risk biomarkers. These results suggest that while early, tech-enabled depression treatment is effective for mental health, it may not be sufficient alone to reduce CVD risk—highlighting the need for alternative or additional interventions to address CVD in this population.

Authors:

Jesse C Stewart1, Jay S Patel2, Brittanny M Polanka3, Sujuan Gao4, John I Nurnberger5, Krysha L MacDonald6, Samir K Gupta7, Robert V Considine7, Richard J Kovacs8, Elizabeth A Vrany9, Jessica Berntson10, Loretta Hsueh11, Aubrey L Shell12, Bruce L Rollman13, Christopher M Callahan14

Affiliations

1Department of Psychology, Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, IN, USA. Electronic address: jstew@iupui.edu.

2Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

3Division Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA.

4Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA.

5Department of Psychiatry and Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.

6Sandra Eskenazi Mental Health Center, Eskenazi Health, Indianapolis, IN, USA.

7Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

8Division of Cardiovascular Disease, Indiana University School of Medicine, Indianapolis, IN, USA.

9Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.

10Dr. Jessica Berntson Inc., Coquitlam, BC, Canada.

11Department of Psychology, University of Illinois Chicago, Chicago, IL, USA.

12Department of Psychology, Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, IN, USA.

13Center for Behavioral Health, Media, and Technology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

14Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Sandra Eskenazi Center for Brain Care Innovation, Eskenazi Health, Indianapolis, IN, USA.

Partners

Related News

infographic showing findings of study

Examining how insurance coverage shapes access to kidney transplantation

Regenstrief researchers contribute to a national study highlighting differences between Medicare Advantage and traditional Medicare  For people with kidney

Tarik Yuce, MD, Jiang Bian, PhD, Serena Guo, MD, PhD, Xing He, PhD, Yu Huang, PhD

GLP-1 medications linked to greater loss of regained weight after bariatric surgery

Study involving Regenstrief researchers uses real-world evidence to evaluate an option for managing weight recurrence  People who regain weight

image of a doctor consulting with a patient

Scalable approach could improve early detection of cognitive impairment in primary care

Regenstrief-led study evaluates how existing health data and patient-reported information could help clinicians identify individuals who need further assessmentEarly

Christopher Callahan, MD

Regenstrief Institute scientist named next president and CEO of Regenstrief Foundation 

Longtime Regenstrief investigator and former IU Center for Aging Research director will assume Foundation leadership in summer 2027.  Christopher